Related Experiment Video
Updated: Jan 11, 2026
07:50
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
3.1K
Emerging Thrombolysis Technologies in Vascular Thrombosis.
Bingwen Eugene Fan1,2,3,4, Yixin Jamie Kok5, Chuen Wen Tan6
1Department of Haematology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
Journal of Clinical Medicine
|November 13, 2025
Summary
Emerging non-pharmacological thrombolysis technologies offer safer, targeted clot removal for thrombotic diseases. Innovations like ultrasound-mediated thrombolysis and microrobots show promise, but require further development for clinical use.
Area of Science:
- Biomedical Engineering
- Cardiovascular Research
- Medical Technology
Background:
- Thrombotic diseases are major causes of death globally.
- Current thrombolytic therapies have significant bleeding risks and limited efficacy.
- Need for advanced, targeted, and minimally invasive treatment strategies.
Purpose of the Study:
- Review emerging non-pharmacological thrombolysis technologies.
- Assess mechanisms, efficacy, and safety of innovative approaches.
- Evaluate translational potential for clinical application.
Main Methods:
- Narrative synthesis of recent advancements.
- Focus on ultrasound-mediated thrombolysis (UMT), microrobots, electrothrombectomy, photothrombectomy, magnetic targeted thrombolysis, and nanotechnology.
- Review of preclinical and clinical studies.
Main Results:
- UMT and fibrin-targeted nanoparticles show promising recanalization.
- Electrothrombectomy demonstrated safe and effective clot extraction in human trials.
- Microrobots and photothrombectomy are still in preclinical development.
Conclusions:
- Novel thrombolysis technologies offer safer, targeted alternatives.
- Clinical adoption hinges on overcoming challenges like scalability and biocompatibility.
- Future directions include hybrid approaches and real-time imaging integration.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
271
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
271
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
293
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
293
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
01:30Venous Thrombosis I: Introduction
334
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
334
01:16Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K